$3.11
0.17[5.78%]
At close: Apr 29
$3.11
0[0.00%]
PreMarket: 8:16AM EDT
MAIA Biotechnology
(AMEX:MAIA)Latest News for MAIA Biotechnology Stock (AMEX:MAIA)
MAIA Biotechnology Stock (AMEX: MAIA)
Categories: All
Monday, April 29, 2024
Tuesday, April 23, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
Friday, March 22, 2024
Wednesday, March 13, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
Thursday, February 22, 2024
Wednesday, February 07, 2024
Tuesday, February 06, 2024
Wednesday, January 31, 2024
Wednesday, January 24, 2024
Thursday, January 18, 2024
Wednesday, January 17, 2024
Monday, January 15, 2024
Friday, January 12, 2024
- Why Wipro Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Jan 12, 2024, 1:28PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Jan 12, 2024, 12:31PM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Jan 12, 2024, 8:05AM
- Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Jan 12, 2024, 7:52AM
Tuesday, January 09, 2024
Tuesday, December 19, 2023
Thursday, November 16, 2023
Wednesday, November 15, 2023
- Why MAIA Biotechnology Stock Is Nosediving During Wednesday's SessionHenry Khederian - Nov 15, 2023, 10:42AM
- MAIA Biotechnology shares are trading lower after the company announced a $4 million registered direct offering.Benzinga Newsdesk - Nov 15, 2023, 10:40AM
- MAIA Biotechnology Announces $4M Registered Direct Offering Of 2,424,243 Of Its Shares Of Common Stock At A Purchase Price Of $1.65 Per ShareBenzinga Newsdesk - Nov 15, 2023, 9:35AM
Friday, November 10, 2023
Tuesday, November 07, 2023
Tuesday, October 31, 2023
Monday, October 30, 2023
- MAIA Biotechnology Announces Results From Investigational New Drug Enabling Study; Says 'Study results warrant further in vivo in-depth investigation of THIO conjugates as second generation cancer therapies'Benzinga Newsdesk - Oct 30, 2023, 8:43AM
- MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung CancerJeremy Golden - Oct 30, 2023, 8:33AM
Thursday, October 19, 2023
Tuesday, October 17, 2023
Monday, October 16, 2023
Thursday, October 12, 2023
Tuesday, October 10, 2023
- MAIA Biotechnology Accelerates Enrollment In THIO-101 Phase II Clinical Trial As Efficacy Is Observed Is Dosed PatientsBill Haddad - Oct 10, 2023, 11:15AM
- Maia Biotechnology Says Its Lead Asset THIO Showed Highly Potent Anticancer Activity In Gliomas, An Aggressive Type Of Brain Tumor That Originates From Glial Cells; THIO Was Evaluated In Various In Vitro And In Vivo Models Of GliomasBenzinga Newsdesk - Oct 10, 2023, 8:08AM
Thursday, October 05, 2023
Tuesday, October 03, 2023
- MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung CancerNabaparna Bhattacharya - Oct 3, 2023, 1:25PM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Oct 3, 2023, 9:06AM
- MAIA Biotechnology Announces FDA Clearance Of IND Application For THIO, A First-in-Class Telomere Targeting Agent For Treating Non-Small Cell Lung CancerBenzinga Newsdesk - Oct 3, 2023, 8:03AM